American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I

27 April 2020 - 28 April 2020

Blood test enables early detection of multiple cancers in women with no cancer history

18 May 2020 by

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Blood test enables early detection of multiple cancers in women with no cancer history

18 May 2020

KEYNOTE-042: Pembrolizumab monotherapy works in PD-L1–positive advanced NSCLC regardless of STK11 or KEAP1 status

14 May 2020 by

Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.

KEYNOTE-042: Pembrolizumab monotherapy works in PD-L1–positive advanced NSCLC regardless of STK11 or KEAP1 status

14 May 2020

Talazoparib improves PROs, but not OS, in germline BRCA1/2-mutated, HER2-negative advanced breast cancer

13 May 2020 by

The oral PARP inhibitor talazoparib significantly improves patient-reported outcomes (PROs), but not overall survival (OS), compared with physician’s choice of chemotherapy (PCT) in patients with locally advanced or metastatic HER2-negative breast cancer with a germline BRCA1/2 mutation, final results of the phase III EMBRACA trial have shown.

Talazoparib improves PROs, but not OS, in germline BRCA1/2-mutated, HER2-negative advanced breast cancer

13 May 2020

Atezolizumab plus enzalutamide does not improve OS or cancer control vs enzalutamide in metastatic CRPC

12 May 2020 by

Atezolizumab, given in combination with enzalutamide, did not show improvement in overall survival (OS) or cancer control compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC), resulting in early termination of the phase III IMbassador250 study.

Atezolizumab plus enzalutamide does not improve OS or cancer control vs enzalutamide in metastatic CRPC

12 May 2020

Pneumonitis history linked to ICI/chemo-related pneumonitis in NSCLC patients

12 May 2020 by

Patients with advanced non-small-cell lung cancer (NSCLC) who have a past medical history of pneumonitis are at increased risk of treatment-related pneumonitis (TAP) from immune checkpoint inhibitor (ICI) regimens or chemotherapy alone, an analysis of clinical trial and real-world data has shown.

Pneumonitis history linked to ICI/chemo-related pneumonitis in NSCLC patients

12 May 2020

Durvalumab/olaparib/paclitaxel combo improves pCR in high-risk HER2-negative breast cancer

07 May 2020 by

The use of durvalumab in combination with olaparib and paclitaxel significantly improves pathological complete response (pCR) rate vs paclitaxel alone in patients with high-risk HER2-negative stage II/III breast cancer, new results of the I-SPY 2 trial have shown.

Durvalumab/olaparib/paclitaxel combo improves pCR in high-risk HER2-negative breast cancer

07 May 2020